A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)

References

• Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364: 937–52
   Google Scholar
• Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295: 180–9
   PubMed Web of Science ®Google Scholar
• Critchley J, Liu J, Zhao D, et al. Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation 2004;110:1236–44
   PubMed Web of Science ®Google Scholar
• He J, Gu D, Reynolds K, et al. Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hyper cholesterolemia in China. Circulation 2004;110: 405–11
   PubMed Web of Science ®Google Scholar
• Tewari S, Kumar S, Kapoor A, et al. Premature coronary artery disease in North India: an angiography study of 1971 patients. Indian Heart J 2005;57:311–18
   PubMedGoogle Scholar
• Ko M, Kim MT, Nam JJ. Assessing risk factors of coronary heart disease and its risk prediction among Korean adults: the 2001 Korea National Health and Nutrition Examination Survey. Int J Cardiol 2006;110;184–90
   Google Scholar
• Nawawi HM, Nor IM, Noor IM, et al. Current status of coronary risk factors among rural Malays in Malaysia. J Cardiovasc Risk 2002;9:17–23
   PubMedGoogle Scholar
• Chien KL, Sung FC, Hsu HC, et al. Relative importance of atherosclerotic risk factors for coronary heart disease in Taiwan. Eur J Cardiovasc Prev Rehabil 2005;12:95–101
   PubMed Web of Science ®Google Scholar
• Tatsanavivat P, Klungboonkrong V, Chirawatkul A, et al. Prevalence of coronary heart disease and major cardiovascular risk factors in Thailand. Int J Epidemiol 1998;27:405–9
   PubMed Web of Science ®Google Scholar
• Narksawat K, Podhipak A, Punyaratabundhu P, Podang J. Atheromatous risk factors among Thai labor forces by socioeconomic status. J Med Assoc Thai 2003;86:655–65
   PubMedGoogle Scholar
• Wu Y. Overweight and obesity in China. BMJ 2006;333: 362–3
   PubMed Web of Science ®Google Scholar
• Muntner P, Gu D, Reynolds RF, et al. Therapeutic lifestyle changes and drug treatment for high blood cholesterol in China and application of the Adult Treatment Panel III guidelines. Am J Cardiol 2005;96:1260–5
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152–60
   PubMed Web of Science ®Google Scholar
• McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003;19:689–98
   PubMed Web of Science ®Google Scholar
• Shepherd J, Hunninghake DB, Barter P, et al. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003;91:11–19C
   Google Scholar
• Schuster H, Barter PJ, Stender S, et al.; Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY) I study. Am Heart J 2004;147: 705–13
   Google Scholar
• Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia - Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials 2006;7:35
   PubMed Web of Science ®Google Scholar
• Tzeng T, Mitchell P, Zhang H, et al. Population pharmacokinetics of rosuvastatin in normal subjects and subjects with dyslipidaemia. Clin Pharmacol Ther 2004;75:P56 [abstract PII–18]
   Google Scholar
• Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78:330–41
   PubMed Web of Science ®Google Scholar
• Tirona RG. Ethnic differences in statin disposition. Clin Pharmacol Ther 2005;78:311–16
   PubMed Web of Science ®Google Scholar
• Wu CC, Sy R, Tanphaichitr V, et al. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol – a multinational, multicenter, double-blind study. J Formos Med Assoc 2002;101:478–87
   PubMed Web of Science ®Google Scholar
• Wang A, Yu BN, Luo CH, et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 2005;60:843–8
   PubMed Web of Science ®Google Scholar
• Saito Y, Goto Y, Dane A, et al. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2003;10:329–36
   PubMedGoogle Scholar
• Lu T, Ding Y, Leu H, et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hyper-cholesterolemia. Am J Cardiol 2004;94:157–61
   PubMed Web of Science ®Google Scholar
• Mabuchi H, Nohara A, Higashikata T, et al. Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2004;11:152–8
   PubMedGoogle Scholar
• Middleton A, Binbrek AS, Fonseca FAH, et al. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Curr Med Res Opin 2006;22:1181–91
   PubMed Web of Science ®Google Scholar
• Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434–503
   Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10(Suppl 1):S2–78
   Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502
   Google Scholar
• Kendrach MG, Kelly-Freeman M. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacother 2004;38:1286–92
   PubMed Web of Science ®Google Scholar
• Miller PS, Smith DG, Jones P. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). Am J Cardiol 2005;95:1314–19
   Google Scholar
• Insull W Jr, Ghali JK, Hassman DR. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc 2007;82:543–50
   Google Scholar
• Strandberg TE, Feely J, Sigurdsson EL. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin Ther 2004;26: 1821–33
   Google Scholar
• Bots AFE, Kastelein JJP; Discovery Netherlands Investigators. Achieving lipid goals in real life: the Dutch DISCOVERY study. Int J Clin Pract 2005;59:1387–94
   Google Scholar
• Fonseca FAH, Ruiz A, Cardona-Muñoz EG, et al. The DISCOVERY PENTA study: a DIrect Statin cOmparison of LDL-C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr Med Res Opin 2005;21: 1307–15
   Google Scholar
• Binbrek AS, Elis A, Al-Zaibag M, et al. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: a randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study). Curr Ther Res 2006;67:21–43
   Google Scholar
• Middleton A, Fuat A. Achieving lipid goals in real life: the DISCOVERY-UK study. Br J Cardiol 2006;13:72–6
   Web of Science ®Google Scholar
• Jukema JW, Liem AH, Dunselman PH, et al. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr Med Res Opin 2005;21:1865–74
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BH, Franken AA, Vincent HH; Dutch Corall Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study. J Intern Med 2005;257: 531–9
   Google Scholar
• NCEP ATP III. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
   PubMed Web of Science ®Google Scholar
• Zhou BF. Effect of body mass index on all-cause mortality and incidence of cardiovascular diseases report for meta-analysis of prospective studies open optimal cut-off points of body mass index in Chinese adults. Biomed Environ Sci 2002;15: 245–52
   PubMed Web of Science ®Google Scholar
• Zhou BF; Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults – study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci 2002;15:83–96
   Google Scholar
• Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469–80
   Google Scholar
• Milionis HJ, Liberopoulos EN, Elisaf M, et al. Analysis of antihypertensive effects of statins. Curr Hypertens Rep 2007;9:175–83
   PubMed Web of Science ®Google Scholar
• Kostis JB. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther 2007;21:297–309
   PubMed Web of Science ®Google Scholar
• Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004;102:52–60
   PubMed Web of Science ®Google Scholar
• Vidt DG, Harris S, McTaggart F, et al. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 2006;97:1602–6
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou A, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Education Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220–8
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:23–33
   PubMed Web of Science ®Google Scholar
• Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004;94:882–8
   PubMed Web of Science ®Google Scholar
• Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006;97(Suppl):61–8C
   Google Scholar
• McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87:28–32B
   Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97(Suppl):52–60C
   Google Scholar
• Ito MK, Delucca GM, Aldridge MA. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events. J Cardiovasc Pharmacol Ther 2001;6:129–35
   Google Scholar